financetom
Business
financetom
/
Business
/
FOBI AI Applies to Launch US$2.2 Million Private Placement
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
FOBI AI Applies to Launch US$2.2 Million Private Placement
Dec 30, 2024 4:36 AM

07:06 AM EST, 12/30/2024 (MT Newswires) -- FOBI AI ( FOBIF ) over the weekend said it has applied to the British Columbia Securities Commission to complete a US$2.2 million non-brokered private pavement.

The offering is for roughly 56.1 million units to a single subscriber at US$0.04 per unit.

Each unit is composed of one common share and one common share purchase warrant, exercisable for the purchase of one additional common share at US$0.06 apiece for a two-year period from the offering's closing date.

Proceeds will be used to file the company's outstanding continuous disclosure documents, cover essential expenses and apply for a full revocation of the failure-to-file cease trade order, among other things.

At the offering's closing, the subscriber will hold 20% of FOBI AI's ( FOBIF ) issued and outstanding common shares.

The private placement is conditional on the Commission granting the partial revocation of an ongoing failure-to-file cease trade order as well as the approval by the TSX Venture Exchange and the execution of a subscription agreement, among other things.

The company anticipates filing audited annual financial statements, management's discussion and analysis, and related certifications for the year ended June 30, 2024, within 45 days of the offering's closing; and interim financial statements, management's discussion and analysis, and related certifications for the three months ended Sept. 30, 2024, within 15 days of the filing of the annual filings.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Power Nickel Hires Jon Christian Evensen as a Strategic Advisor
Power Nickel Hires Jon Christian Evensen as a Strategic Advisor
Nov 27, 2024
12:57 PM EST, 11/27/2024 (MT Newswires) -- Power Nickel ( PNPNF ) on Wednesday said it engaged Jon Christian Evensen as a strategic advisor to the company. Evensen will advise the board and management on a variety of topics including strategic transactions, capital markets, and maximizing the value of the company's assets for shareholders. As the company looks forward from...
Exclusive-US consumer finance watchdog moves on new rules ahead of Trump takeover
Exclusive-US consumer finance watchdog moves on new rules ahead of Trump takeover
Nov 27, 2024
(Reuters) - The U.S. consumer finance watchdog is moving ahead with rulemaking in the final weeks of Joe Biden's Democratic administration, in a bid to advance consumer protections before President-elect Trump overhauls the agency, said three people familiar with the agency's thinking. The Consumer Financial Protection Bureau hopes to finalize a ban on including medical debt in credit reports, a...
Jayud Global Logistics Regains Compliance With Nasdaq Listing Requirement
Jayud Global Logistics Regains Compliance With Nasdaq Listing Requirement
Nov 27, 2024
12:56 PM EST, 11/27/2024 (MT Newswires) -- Jayud Global Logistics ( JYD ) said Wednesday it regained compliance with Nasdaq's minimum bid price requirement. The company maintained a minimum closing bid price of $1 or more for at least 10 straight business days to meet compliance for listing. Price: 1.13, Change: -0.11, Percent Change: -8.71 ...
Big pharma pushes Trump team to ease Medicare drug price negotiation rules
Big pharma pushes Trump team to ease Medicare drug price negotiation rules
Nov 27, 2024
NEW YORK (Reuters) - The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest prescription drugs once president-elect Donald Trump is back in office, according to lobbyists, executives, analysts and healthcare policy experts. Seven lobbyists and executives who work with top pharmaceutical and biotech companies told Reuters they are pushing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved